



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: GOODWIN et al.

Docket No.: 2804

Serial No: 09/628,126

Group Art Unit: 1642

Filed: July 28, 2000

Examiner: S. Huff

For: CD30 LIGAND


RECEIVED
JUN 16 2003
TECH CENTER 1600/2800

DECLARATION UNDER 37 C.F.R. § 1.132

Sir:

We, the undersigned, do hereby declare and state:

1. We are three of the co-inventors of the invention disclosed and claimed in above-referenced patent application.
2. We are co-authors of WO 93/24135 and co-inventors of the invention disclosed and claimed therein. This publication was prepared from our research records.
3. We and Hans-Juergen Gruss mutually participated in the conception, research and reduction to practice of the invention disclosed and claimed in the instant patent application.
4. Material not disclosed in WO 93/24135 but present in the instant application was prepared from our research records along with those of Hans-Juergen Gruss.
5. We further declare that all statements made herein of our own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.



Craig A. Smith

5/29/03


Date



Raymond G. Goodwin

5/28/03

Date



Richard J. Armitage
ee272602 5/27/03

5/29/03

Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: GOODWIN et al.

Docket No.: 2804-I

Serial No: 09/628,126

Group Art Unit: 1642

Filed: July 28, 2000

Examiner: S. Huff

For: CD30 LIGAND

RECEIVED
JUN 18 2003
TECH CENTER 1600/2900

DECLARATION UNDER 37 C.F.R. § 1.132

Sir:

We, the undersigned, do hereby declare and state:

1. We are co-inventors of the invention described and claimed in above-referenced patent application.
2. We are among the co-authors of Smith et al., *Cell* 73:1349 (1993).
3. Elizabeth Baker and Grant R. Sutherland were employed in the Department of Cytogenetics and Molecular Genetics, Adelaide Children's Hospital, North Adelaide, South Australia. At our request and using reagents we provided, they performed the chromosomal mapping of human CD30L as described in Smith et al.
4. Camilynn I. Brannan, Nancy Jenkins and Neal Copeland were employed in the Mammalian Genetics Laboratory of the National Cancer Institute, in Frederick, Maryland. At our request and using reagents we provided, they performed the chromosomal mapping of murine CD30L as described in Smith et al.
5. The remaining co-authors were, at the time the work described in the paper was done, co-employees of Immunex Corporation, assignee of the above-referenced patent application.
6. Dirk Anderson prepared the cDNA library(ies) from which CD30L cDNA was isolated. He provided the library(ies) to us based on our desire for material from particular types of cells, and we used our reagents and experimental design to isolate the CD30L cDNA.
7. At our request and using reagents we provided, Benjamin Falk assisted in the screening of cDNA libraries and performed the anchored PCR reactions to isolate the 5' ends of the human and murine cDNAs.
8. At our request and using reagents we provided, Wenie Din assisted in the slide screening and performed the Northern Blot analysis.
9. At our request and using reagents we provided, Terri Davis assisted in the screening of cDNA libraries and in the analysis and characterization of CD30L.
10. At our request and using reagents we provided, Steve Gimpel sequenced the CD30L DNA.


11. At our request and using reagents we provided William Fanslow and Mark Alderson conducted experiments analyzing binding of CD30-Fc to certain types of cells.

12. At our request and using reagents we provided, Brian Glinak and Ian B. McAllister performed assays to characterize the biological activity(ies) of CD30L.


13. At our request and using reagents we provided, Terry Farah assisted in the analysis of the CD30L sequence and its relationship to other members of the Tumor Necrosis Factor family of ligands.

14. At our request, subsequent to isolating CD30L cDNA and drafting a manuscript that eventually was published as the aforementioned paper, Steven Gillis and Kenneth H. Grabstein provided critical review of the manuscript.


15. We further declare that all statements made herein of our own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.




Craig A. Smith




Date



Raymond G. Goodwin



Date



Richard J. Armitage



Date

Hans-Juergen Gruss

Date